Bicyclic CX3CR1 receptor agonists
US12258337B2 · kind B2 · utility
0Cited by
3References
13Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 19, 2023 |
| Grant date | Mar 25, 2025 |
| Priority date | — |
| Expiry date | Sep 19, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2602/32
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.